OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

查看量	下载量

相关文章
更多...

PLOS ONE 2013

Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease

DOI: 10.1371/journal.pone.0076555

Solaleh Emamgholipour, Seyede Mahdieh Eshaghi, Arash Hossein-nezhad, Khadijeh Mirzaei, Zhila Maghbooli, Mohammad Ali Sahraian

Full-Text Cite this paper Add to My Lib

Abstract:

Background Adipocytokines may be involved in multiple sclerosis (MS) as well as other autoimmune and inflammatory-related diseases. This study aims to compare levels of resistin, visfatin and leptin in three subgroups of MS patients with healthy subjects and also to study their relationship with Foxp3 expression and levels of several pro-inflammatory mediators such as interleukine-1 β(IL-1 β),tumor necrosis factor-α (TNF-α) and human sensitive C-reactive protein (hs-CRP). Methods A total of 391 subjects including 200 healthy controls and 191 MS patients were recruited for this case-control study. Circulating adipocytokines and inflammatory mediators were measured using immunoassay methods. Foxp3 gene expression in peripheral blood mononuclear cells (PBMC) was determined by quantitative real-time PCR. Fat tissue mass was evaluated by using dual energy X-ray absorptiometery (DEXA). Results A significant difference was observed in levels of inflammatory mediators, adipocytokines, Foxp3 gene expression and adipose tissue mass between MS patients and healthy controls. All adipocytokines were positively correlated with levels of inflammatory mediators and negatively correlated with Foxp3 expression in MS patients. In controls, there were positive correlations between circulating leptin and resistin with TNF-α and IL-1β in subgroup analysis, the highest levels of TNF-α, IL-1β, hs-CRP, resistin and leptin were observed in primary progressive-MS (PP-MS) patients. Also, expression of Foxp3 and levels of visfatin in relapsing remitting-MS(RR-MS) patients were higher compared with the other subgroups. Conclusions Our findings suggest the potential role of adipocytokines in pathogenesis and severity of MS. Notably, the relationship of adipocytokines levels with inflammatory cytokines as well as clinical features of MS could be considerable in translational medicine and biomarker studies.

References

[1]	Su KG, Banker G, Bourdette D, Forte M (2009) Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 9: 411-417. doi:10.1007/s11910-009-0060-3. PubMed: 19664372.
[2]	Lassmann H, Brück W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7: 115-121. doi:10.1016/S1471-4914(00)01909-2. PubMed: 11286782.
[3]	Bennett JL, Stüve O (2009) Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 32: 121-132. doi:10.1097/WNF.0b013e3181880359. PubMed: 19483479.
[4]	Graber JJ, Dhib-Jalbut S (2011) Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 305: 1-10. doi:10.1016/j.jns.2011.03.026. PubMed: 21463872.
[5]	Kasper LH, Shoemaker J (2010) Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology 74 Suppl 1: S2-S8. doi:10.1212/WNL.0b013e3181cb86a1. PubMed: 20038759.
[6]	Martins TB, Rose JW, Jaskowski TD, Wilson AR, Husebye D et al. (2011) Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 136: 696-704. doi:10.1309/AJCP7UBK8IBVMVNR. PubMed: 22031307.
[7]	Venken K, Hellings N, Liblau R, Stinissen P (2010) Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 16: 58-68. doi:10.1016/j.molmed.2009.12.003. PubMed: 20159585.
[8]	Fritzsching B, Haas J, Konig F, Kunz P, Fritzsching E et al. (2011) Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLOS ONE 6: e17988. doi:10.1371/journal.pone.0017988. PubMed: 21437244.
[9]	Bettini M, Vignali DA (2009) Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 21: 612-618. doi:10.1016/j.coi.2009.09.011. PubMed: 19854631.
[10]	Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336. doi:10.1038/ni904. PubMed: 12612578.
[11]	Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27. doi:10.1111/j.0105-2896.2006.00427.x. PubMed: 16903903.
[12]	Alatab S, Maghbooli Z, Hossein-Nezhad A, Khosrofar M, Mokhtari F (2011) Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes. Minerva Med 102: 461-468. PubMed: 22193377.
[13]	Bjerg L, Brosbol-Ravnborg A, Torring C, Dige A, Bundgaard B et al. (2012) Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 249: 76-82. doi:10.1016/j.jneuroim.2012.04.012. PubMed: 22608884.
[14]	Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C et al. (2011) T regulatory cells are markers of disease activity in multiple sclerosis patients. PLOS ONE 6: e21386. doi:10.1371/journal.pone.0021386. PubMed: 21731726.
[15]	Mikulkova Z, Praksova P, Stourac P, Bednarik J, Michalek J (2011) Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 300: 135-141. doi:10.1016/j.jns.2010.08.053. PubMed: 20884014.
[16]	Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V et al. (2005) Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 102: 5150-5155. doi:10.1073/pnas.0408995102. PubMed: 15788534.
[17]	Mirzaei K, Hossein-nezhad A, Mokhtari F, Najmafshar A, Nikoo MK (2011) VISFATIN/NAMPT/PBCEF and cytokine concentration in multiple sclerosis patients compared to healthy subjects. Eur J Inflamm 9: 31-37.
[18]	Kraszula L, Jasinska A, Eusebio M, Kuna P, Glabinski A et al. (2012) Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol 46: 22-28. PubMed: 22426759.
[19]	Otero M, Lago R, Lago F, Casanueva FF, Dieguez C et al. (2005) Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579: 295-301. doi:10.1016/j.febslet.2004.11.024. PubMed: 15642335.
[20]	Busso N, So A, Chobaz-Peclat V, Morard C, Martinez-Soria E et al. (2002) Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 168: 875-882. PubMed: 11777985.
[21]	Gove ME, Rhodes DH, Pini M, van Baal JW, Sennello JA et al. (2009) Role of leptin receptor-induced STAT3 signaling in modulation of intestinal and hepatic inflammation in mice. J Leukoc Biol 85: 491-496. PubMed: 19052144.
[22]	Lee CH, Reifsnyder PC, Naggert JK, Wasserfall C, Atkinson MA et al. (2005) Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: I. Pathophysiological analysis. Diabetes 54: 2525-2532. doi:10.2337/diabetes.54.9.2525. PubMed: 16123339.
[23]	Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK et al. (2001) Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 166: 5909-5916. PubMed: 11342605.
[24]	Robinson WH, Utz PJ, Steinman L (2003) Genomic and proteomic analysis of multiple sclerosis. Opinion. Curr Opin Immunol 15: 660-667. doi:10.1016/j.coi.2003.09.015. PubMed: 14630200.
[25]	Filkova M, Haluzik M, Gay S, Senolt L (2009) The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 133: 157-170. doi:10.1016/j.clim.2009.07.013. PubMed: 19740705.
[26]	Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83: 804-816. doi:10.1189/jlb.0807581. PubMed: 18252866.
[27]	Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A et al. (2009) Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLOS ONE 4: e7897. doi:10.1371/journal.pone.0007897. PubMed: 19936064.
[28]	Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL et al. (2008) Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 181: 4685-4695. PubMed: 18802071.
[29]	Carbone F, La Rocca C, Matarese G (2012) Immunological functions of leptin and adiponectin. Biochimie 94: 2082-2088. doi:10.1016/j.biochi.2012.05.018. PubMed: 22750129.
[30]	Procaccini C, Jirillo E, Matarese G (2012) Leptin as an immunomodulator. Mol Aspects Med 33: 35-45. doi:10.1016/j.mam.2011.10.012. PubMed: 22040697.
[31]	Stofkova A (2010) Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 44: 25-36. doi:10.4149/endo_2010_01_25. PubMed: 20151765.
[32]	Dahl TB, Holm S, Aukrust P, Halvorsen B (2012) Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 32: 229-243. doi:10.1146/annurev-nutr-071811-150746. PubMed: 22462624.
[33]	Alatab S, Hossein-nezhad A, Mirzaei K, Mokhtari F, Shariati G et al. (2011) Inflammatory profile, age of onset, and the MTHFR polymorphism in patients with multiple sclerosis. J Mol Neurosci 44: 6-11. doi:10.1007/s12031-010-9486-y. PubMed: 21190091.
[34]	Hietaharju A, Kuusisto H, Nieminen R, Vuolteenaho K, Elovaara I et al. (2010) Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study. Eur J Neurol 17: 332-334. doi:10.1111/j.1468-1331.2009.02701.x. PubMed: 19538214.
[35]	Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. doi:10.1126/science.1078231. PubMed: 12532024.
[36]	Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E et al. (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697. doi:10.1016/j.immuni.2008.03.016. PubMed: 18468463.
[37]	Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O (2008) Leptin beyond body weight regulation--current concepts concerning its role in immune function and inflammation. Cell Immunol 252: 139-145. doi:10.1016/j.cellimm.2007.09.004. PubMed: 18289518.
[38]	Chatzantoni K, Papathanassopoulos P, Gourzoulidou E, Mouzaki A (2004) Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS) In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients. J Autoimmun 23: 169-177. doi:10.1016/j.jaut.2004.05.007. PubMed: 15324935.
[39]	Frisullo G, Angelucci F, Mirabella M, Caggiula M, Patanella K et al. (2004) Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients. J Clin Immunol 24: 287-293. doi:10.1023/B:JOCI.0000025450.48267.a5. PubMed: 15114059.
[40]	Lambert CP, Lee Archer R, Evans WJ (2002) Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 83: 1559-1561. doi:10.1053/apmr.2002.35663. PubMed: 12422325.
[41]	Sioka C, Fotopoulos A, Georgiou A, Papakonstantinou S, Pelidou SH et al. (2011) Body composition in ambulatory patients with multiple sclerosis. J Clin Densitom 14: 465-470. doi:10.1016/j.jocd.2011.04.012. PubMed: 21835661.
[42]	Fantuzzi G (2009) Three questions about leptin and immunity. Brain Behav Immun 23: 405-410. doi:10.1016/j.bbi.2008.10.007. PubMed: 18996468.
[43]	MacLaren R, Cui W, Cianflone K (2008) Adipokines and the immune system: an adipocentric view. Adv Exp Med Biol 632: 1-21. doi:10.1007/978-0-387-78952-1_1. PubMed: 19025110.
[44]	Gutierrez DA, Puglisi MJ, Hasty AH (2009) Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep 9: 26-32. doi:10.1007/s11892-009-0006-9. PubMed: 19192421.
[45]	Mahler A, Steiniger J, Bock M, Brandt AU, Haas V et al. (2012) Is metabolic flexibility altered in multiple sclerosis patients? PLOS ONE 7: e43675. doi:10.1371/journal.pone.0043675. PubMed: 22952735.
[46]	Grégoire F, De Broux N, Hauser N, Heremans H, Van Damme J et al. (1992) Interferon-gamma and interleukin-1 beta inhibit adipoconversion in cultured rodent preadipocytes. J Cell Physiol 151: 300-309. doi:10.1002/jcp.1041510211. PubMed: 1572904.
[47]	Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A et al. (2006) Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 49: 2162-2173. doi:10.1007/s00125-006-0335-z. PubMed: 16865359.
[48]	Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556. doi:10.1210/jc.2004-0395. PubMed: 15181022.
[49]	De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S et al. (2007) A key role of leptin in the control of regulatory T cell proliferation. Immunity 26: 241-255. doi:10.1016/j.immuni.2007.01.011. PubMed: 17307705.
[50]	Hubert S, Rissiek B, Klages K, Huehn J, Sparwasser T et al. (2010) Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med 207: 2561-2568. doi:10.1084/jem.20091154. PubMed: 20975043.
[51]	Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I (2011) Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J Neuroimmunol 234: 141-147. doi:10.1016/j.jneuroim.2011.02.009. PubMed: 21397339.
[52]	van Boxel-Dezaire AH, Smits M, van Trigt-Hoff SC, Killestein J, van Houwelingen JC et al. (2001) Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis. J Neuroimmunol 120: 152-160. doi:10.1016/S0165-5728(01)00398-8. PubMed: 11694330.
[53]	Duran I, Martinez-Caceres EM, Brieva L, Tintore M, Montalban X (2001) Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis. Mult Scler 7: 151-156. doi:10.1177/135245850100700303. PubMed: 11475437.
[54]	Hong J, Li H, Chen M, Zang YC, Skinner SM et al. (2009) Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis. Int Immunol 21: 1329-1340. doi:10.1093/intimm/dxp100. PubMed: 19822525.
[55]	Venken K, Hellings N, Thewissen M, Somers V, Hensen K et al. (2008) Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79-89. doi:10.1111/j.1365-2567.2007.02690.x. PubMed: 17897326.
[56]	Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G et al. (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5: 343-354. doi:10.1016/S1474-4422(06)70410-0. PubMed: 16545751.
[57]	Suh SW, Hamby AM, Swanson RA (2007) Hypoglycemia, brain energetics, and hypoglycemic neuronal death. Glia 55: 1280-1286. doi:10.1002/glia.20440. PubMed: 17659530.
[58]	Wang J, Zhai Q, Chen Y, Lin E, Gu W et al. (2005) A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 170: 349-355. doi:10.1083/jcb.200504028. PubMed: 16043516.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133